Literature DB >> 11124307

A comparison of dorzolamide-timolol combination versus the concomitant drugs.

S Choudhri1, M Wand, M B Shields.   

Abstract

PURPOSE: To compare the intraocular pressure (IOP) lowering effect of fixed combination dorzolamide 2% and timolol 0.5% therapy to that of concomitant administration of a topical beta-blocker and dorzolamide.
METHODS: Seventy-four consecutive glaucoma patients were changed from a regimen including a topical beta-blocker and dorzolamide to the fixed combination dorzolamide-timolol in 1 eye, with the other eye used as the control. The average IOP readings before and 1 month after the change were compared.
RESULTS: The mean baseline IOP in the entire study population was 19.4 +/- 4.2 mm Hg in the study eyes and 16.9 +/- 4.2 mm Hg in the control eyes. Four weeks after the medication change, the mean IOP was 17.3 +/- 3.9 mm Hg in the study eyes (P <.001) and 16.1 +/- 4.1 mm Hg in the control eyes (P =.02). The difference between the mean IOP change of 2.1 mm Hg in the study eyes and 0.8 mm Hg in the control eyes was found to be statistically significant (P =.01).
CONCLUSION: These findings suggest that the fixed combination dorzolamide-timolol therapy achieves additional lowering of the intraocular pressure compared with the concomitant administration of a beta-blocker and dorzolamide.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11124307     DOI: 10.1016/s0002-9394(00)00717-0

Source DB:  PubMed          Journal:  Am J Ophthalmol        ISSN: 0002-9394            Impact factor:   5.258


  16 in total

1.  Three-month evaluation of dorzolamide hydrochloride/timolol maleate fixed-combination eye drops versus the separate use of both drugs.

Authors:  Kenji Inoue; Minako Shiokawa; Michitaka Sugahara; Masato Wakakura; Shoichi Soeda; Goji Tomita
Journal:  Jpn J Ophthalmol       Date:  2012-09-22       Impact factor: 2.447

Review 2.  Topical dorzolamide 2%/timolol 0.5% ophthalmic solution: a review of its use in the treatment of glaucoma and ocular hypertension.

Authors:  James E Frampton; Caroline M Perry
Journal:  Drugs Aging       Date:  2006       Impact factor: 3.923

Review 3.  Ophthalmic drug discovery: novel targets and mechanisms for retinal diseases and glaucoma.

Authors:  Kang Zhang; Liangfang Zhang; Robert N Weinreb
Journal:  Nat Rev Drug Discov       Date:  2012-06-15       Impact factor: 84.694

4.  Clinical efficacy and neuroprotective effects of brimonidine in the management of glaucoma and ocular hypertension.

Authors:  Anna Galanopoulos; Ivan Goldberg
Journal:  Clin Ophthalmol       Date:  2009-06-02

5.  Considerations in glaucoma therapy: fixed combinations versus their component medications.

Authors:  Eve J Higginbotham
Journal:  Clin Ophthalmol       Date:  2010-02-02

6.  Efficacy and tolerability of a fixed-dose moxifloxacin - dexamethasone formulation for topical prophylaxis in LASIK: a comparative, double-masked clinical trial.

Authors:  Mauro Campos; Mariana Avila; Anelise Wallau; Cristina Muccioli; Ana Luisa Höfling-Lima; Rubens Belfort
Journal:  Clin Ophthalmol       Date:  2008-06

Review 7.  Use of fixed-dose combination drugs for the treatment of glaucoma.

Authors:  Albert S Khouri; Tony Realini; Robert D Fechtner
Journal:  Drugs Aging       Date:  2007       Impact factor: 3.923

8.  Intraocular pressure reduction using a fixed combination of timolol maleate 0.5% and brimonidine tartrate 0.2% administered three times daily.

Authors:  Elad Moisseiev; Shimon Kurtz; Moshe Lazar; Gabi Shemesh
Journal:  Clin Ophthalmol       Date:  2013-06-25

9.  Tolerability and effectiveness of preservative-free dorzolamide-timolol (preservative-free COSOPT) in patients with open-angle glaucoma or ocular hypertension.

Authors:  Cindy Hutnik; David Neima; Fahim Ibrahim; Robert Scott; Julie Vaillancourt; Denis Haine; John S Sampalis; Natacha Bastien; Sylvain Foucart
Journal:  Clin Ophthalmol       Date:  2010-07-21

10.  Additive intraocular pressure-lowering effect of dorzolamide 1%/timolol 0.5% fixed combination on prostaglandin monotherapy in patients with normal tension glaucoma.

Authors:  Takanori Mizoguchi; Mineo Ozaki; Harumi Wakiyama; Nobuchika Ogino
Journal:  Clin Ophthalmol       Date:  2011-10-14
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.